grinboss

Bio-Techne

TECH

What is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.

At $72.75 (close on November 18) and with the other assumptions at their starting point, Bio-Techne's sales would need to grow 23.0% a year for ten years; over its last decade, the median was 8.1%. Value it with your own assumptions.

Its accounts, year by year

Year endSalesGrowthMargin
06/2016499—32.1%
06/201756312.8%24.0%
06/201864314.2%25.6%
06/201971411.0%25.1%
06/20207393.5%25.7%
06/202193126.0%30.7%
06/20221,10618.7%30.6%
06/20231,1372.8%29.8%
06/20241,1592.0%21.1%
06/20251,2205.2%11.7%
06/20261,215−0.4%24.1%

Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Bio-Techne files with the SEC, the US securities regulator; the latest is for the fiscal year ended June 30, 2026. See the report.

The model's starting point

  • Sales growth, years 1 to 10: 2.8% a year.
  • Sales growth after year 10: 2.5% a year.
  • Operating margin, before stock pay: 21.1% of sales.
  • Working capital needed to grow: $26.0 per $100 of new sales.
  • Capital spending: 3.4% of sales.
  • Stock pay to employees: 7.4% of sales.
  • Discount rate, the same for every company: 10%.

These are the six assumptions the page starts with; each user moves them as they see fit.

Reference points

They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.

For

  • It has more cash than debt.
  • It sold more than the year before in 9 of the last 10 years.
  • It generated free cash flow in each of the last 5 years.
  • Its sales grew 9.3% a year on average over 10 years, from $0.5 billion to $1.2 billion; the median of grinboss companies is 6.6%.

Against

  • It is one of the smallest in grinboss: it sells $1.2 billion a year; the median is $15.1 billion.
  • It ties up $26 in inventory and unpaid customer bills for every $100 of new sales, more than the median ($2).
  • Its stock pay to employees is high: 7.4% of sales, more than the median (1.5%). That is a part of the company that stops belonging to the shareholders.
  • Its margin has fallen over these years, from 26% to 21%.

Other companies in its sector (Health Care)

Thermo Fisher Scientific (TMO) · Universal Health Services (UHS) · Vertex Pharmaceuticals (VRTX) · Viatris (VTRS) · Waters Corporation (WAT) · West Pharmaceutical Services (WST) · Zimmer Biomet (ZBH) · Zoetis (ZTS) · All companies

Loading the model…